CTNNB1 and hemoglobin measurement: The recurrence of mutations at the hotspot residues serine 33 (case 1), glycine 34 (cases 1 and 4), and aspartate 32 (case 14,) within our cohort, as well as the known involvement of CTNNB1 in HB oncogenesis, highlights the likelihood that they are oncogenic drivers.